Home > Archive > 2007 >

Volume 26, Number 4 (December)


Benefits of Pramlintide for Insulin-Using Patients (pages 6-13)

Dale Hamilton, M.D., Saundra Hendricks, M.S., A.P.R.N., Brandon Walsh, Ph.D., and Ken Wilhelm, M.D.

Pramlintide, injected subcutaneously as an adjunct to mealtime insulin, offers improved glycemic control. The authors review the short-term, long-term, and open-label studies as well as a recent study that looked at pramlintide use in people who were not achieving adequate control with basal insulin with or without oral agents.
Drug treatmentPramlintide

Mitigating Cardiovascular Risks in Diabetes (pages 14-17)

Arnaud Bastien, M.D.

Cardiovascular risk modification is a complex issue, and a careful approach is needed to choose effective treatment. Dr. Bastien succinctly outlines the complex interaction of the commonly recognized cardiovascular risk factors in diabetes as well as the less well-recognized risks.
Complications and comorbiditiesCardiovascular disease

Treatment of Erectile Dysfunction in Diabetic Men (pages 18-21)

Ann Ezzell, B.A., and Neil Baum, M.D.

Cialis, Levitra, and Viagra are a common and often effective treatment for erectile dysfunction, but men with diabetes have a lower response rate to these drugs. This article defines nonresponse and covers the proper management of nonresponders.
Complications and comorbiditiesSexual complications
Management strategies and toolsSexual health

Exenatide Use in Real Life (pages 22-27)

Melissa K. Cavaghan, M.D.

Exenatide provides an alternative to weight-promoting therapies for Type 2 diabetes. This case-based review illustrates the advantages that exenatide therapy offered to two patients over alternative agents.
Drug treatmentIncretin mimetics

Rational Therapy of Dyslipidemia in Patients With Type 2 Diabetes (pages 28-33)

Charles A. Reasner, M.D.

People with diabetes often have a mixed lipid disorder referred to as “atherogenic dyslipidemia.” Dr. Reasner outlines a rational approach to the treatment of each abnormality.
Complications and comorbiditiesCardiovascular diseaseDyslipidemia

Investment Advice (pages 34)

Charles A. Reasner, M.D.

A couple of years ago, Exubera sales were projected to be $2 billion a year by 2010. But this October, Pfizer announced that it was pulling Exubera from the market. How did such a promising product unravel in such a short time?
Drug treatmentInsulin

Conversation Maps (pages 39-40)

Linda M. Siminerio, R.N., Ph.D., C.D.E.

Diabetes Conversation Maps are a recent innovation created to facilitate an active dialogue between educators and small groups of diabetes patients. Linda Siminerio explains what they are, the rationale behind them, how they enhance diabetes self-management education, and how you can be trained to use them.